A Phase 3 interventional study of Remdesivir and RDV Placebo in COVID-19, sponsored by Gilead Sciences. Terminated at 63 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.
Among the 40 studies testing remdesivir in COVID-19, this one is the 23rd largest by enrollment, is one of 7 that started in 2021, is one of 17 in phase 3, and was the 27th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 283 across the 40 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in COVID-19 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 9 finished, 9 (100%) have results posted.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is the only one that started in 2021, is one of 6 in phase 3, and was the 7th registered.
Gilead Sciences’s COVID-19 studies by the year they started, since 2020.
4 of the studies testing remdesivir in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies testing remdesivir in COVID-19, from their registry updates:
Among Gilead Sciences’s 10 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).
Key Inclusion Criteria:
Have either:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.
Drug: Remdesivir · Drug: Standard of Care
Participants will receive continued SOC therapy together with RDV matching placebo on Day 1 followed by RDV matching placebo from Day 2 up to Day 5.
Drug: RDV Placebo · Drug: Standard of Care
Administered as Intravenous (IV) infusion once daily
Also known as: GS-5734™, Veklury®
Administered as IV saline once daily
Standard of Care Treatment for COVID-19 Infection
Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29
This is the combined outcome measure reporting the percentage of participants with all-cause death or IMV through Day 29. The reported percentage was from the Kaplan-Meier estimate.
Time frame: First dose date up to Day 29
All-cause Mortality Through Day 29
The reported percentage was from the Kaplan-Meier estimate.
Time frame: First dose date up to Day 29
Percentage of Participants With Initiation of IMV Through Day 29
The reported percentage was the cumulative-incidence estimate.
Time frame: First dose date up to Day 29
Time to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 29
Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death. Cumulative incidence was reported.
Time frame: First dose date up to Day 29
Time to Recovery Independent of Further Worsening by Day 29
Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Cumulative incidence was reported.
Time frame: First dose date up to Day 29
Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 15
Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.
Time frame: Day 15
Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 29
Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.
Time frame: Day 29
Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 29
The number of RRT free days were calculated as the number of full days from Day 1 to Day 29 on which the participant was alive and did not receive RRT.
Time frame: First dose date up to Day 29
Percentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 29
Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.
Time frame: First dose date up to Day 29
Percentage of Participants With Recovery Independent of Further Worsening Through Day 29
Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.
Time frame: First dose date up to Day 29
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
An SAE was defined as an event that, at any dose, results in the following: Death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, a medically important event or reaction which may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes constituting SAEs.
Time frame: First dose date up to last dose date (Maximum: 5 days) plus 30 days
Percentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant administered an investigational drug, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of an investigational drug, whether or not the AE is considered related to the investigational drug.
Time frame: First dose date up to last dose date (Maximum: 5 days)
Participants were enrolled at study sites in Brazil, Portugal, Spain, the United Kingdom, and the United States.
| Milestone | Remdesivir (RDV) | Placebo |
|---|---|---|
| Started | 166 | 83 |
| Completed | 95 | 50 |
| Not completed | 71 | 33 |
| Withdrew: Death | 51 | 25 |
| Withdrew: Lost to follow-up | 9 | 3 |
| Withdrew: Randomized but never treated | 3 | 3 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Withdrew consent | 1 | 2 |
| Withdrew: Investigator's discretion | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
This is the combined outcome measure reporting the percentage of participants with all-cause death or IMV through Day 29. The reported percentage was from the Kaplan-Meier estimate.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29 | 30.2 | 33.5 |
The reported percentage was from the Kaplan-Meier estimate.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| All-cause Mortality Through Day 29 | 25.9 | 29.7 |
The reported percentage was the cumulative-incidence estimate.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants With Initiation of IMV Through Day 29 | 13.8 | 12.8 |
Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death. Cumulative incidence was reported.
| days | Remdesivir (RDV) | Placebo |
|---|---|---|
| Time to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 29 | 20 (7 to NA) | 19 (7 to NA) |
Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Cumulative incidence was reported.
| days | Remdesivir (RDV) | Placebo |
|---|---|---|
| Time to Recovery Independent of Further Worsening by Day 29 | 10 (6 to NA) | 13 (6 to NA) |
Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Score: 1 | 0 | 0 |
| Score: 2 | 48.5 | 48.8 |
| Score: 3 | 5.5 | 2.5 |
| Score: 4 | 9.2 | 7.5 |
| Score: 5 | 6.1 | 11.3 |
| Score: 6 | 8.0 | 5.0 |
| Score: 7 | 4.9 | 6.3 |
| Score: 8 | 17.8 | 18.8 |
Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Score: 1 | 11.7 | 16.3 |
| Score: 2 | 42.9 | 45.0 |
| Score: 3 | 3.1 | 2.5 |
| Score: 4 | 4.3 | 1.3 |
| Score: 5 | 9.2 | 2.5 |
| Score: 6 | 1.8 | 1.3 |
| Score: 7 | 1.8 | 2.5 |
| Score: 8 | 25.2 | 28.8 |
The number of RRT free days were calculated as the number of full days from Day 1 to Day 29 on which the participant was alive and did not receive RRT.
| days | Remdesivir (RDV) | Placebo |
|---|---|---|
| Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 29 | 29 (1 to 29) | 29 (4 to 29) |
Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 29 | 57.7 | 63.8 |
Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants With Recovery Independent of Further Worsening Through Day 29 | 66.3 | 67.5 |
An SAE was defined as an event that, at any dose, results in the following: Death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, a medically important event or reaction which may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes constituting SAEs.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) | 50.3 | 50.0 |
An AE is any untoward medical occurrence in a clinical study participant administered an investigational drug, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of an investigational drug, whether or not the AE is considered related to the investigational drug.
| percentage of participants | Remdesivir (RDV) | Placebo |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs) | 4.9 | 1.3 |
Collected over All-Cause Mortality: Randomization up to last follow-up visit (maximum of 15 weeks); Adverse Events: First dose date up to last dose date (maximum: 5 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remdesivir (RDV) | 55/166 (33.1%) | 82/163 (50.3%) | 60/163 (36.8%) |
| Placebo | 26/83 (31.3%) | 40/80 (50%) | 34/80 (42.5%) |
| Event | Remdesivir (RDV) | Placebo |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 7/163 | 10/80 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 10/163 | 4/80 |
| Cardiac arrestCardiac disorders | 8/163 | 1/80 |
| HypotensionVascular disorders | 7/163 | 0/80 |
| Cardio-respiratory arrestCardiac disorders | 2/163 | 3/80 |
| Covid-19Infections and infestations | 2/163 | 3/80 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/163 | 3/80 |
| Septic shockInfections and infestations | 6/163 | 2/80 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 6/163 | 2/80 |
| SepsisInfections and infestations | 5/163 | 2/80 |
| Event | Remdesivir (RDV) | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 12/163 | 7/80 |
| HypokalaemiaMetabolism and nutrition disorders | 5/163 | 7/80 |
| AnxietyPsychiatric disorders | 5/163 | 7/80 |
| HyperkalaemiaMetabolism and nutrition disorders | 13/163 | 1/80 |
| HypertensionVascular disorders | 4/163 | 6/80 |
| NauseaGastrointestinal disorders | 12/163 | 3/80 |
| HypotensionVascular disorders | 12/163 | 4/80 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/163 | 5/80 |
| AnaemiaBlood and lymphatic system disorders | 10/163 | 1/80 |
| Atrial fibrillationCardiac disorders | 7/163 | 4/80 |
Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study drug.
| Age, Continuous(years) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Mean | 68 ± 14.1 | 71 ± 13.0 | 69 ± 13.8 |
| Age, Customized(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Age Categorical — < 18 Years | 0 | 0 | 0 |
| Age Categorical — >= 18 to < 65 Years | 70 | 22 | 92 |
| Age Categorical — >= 65 Years | 93 | 58 | 151 |
| Sex: Female, Male(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Female | 71 | 33 | 104 |
| Male | 92 | 47 | 139 |
| Ethnicity (NIH/OMB)(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 8 | 31 |
| Not Hispanic or Latino | 135 | 72 | 207 |
| Unknown or Not Reported | 5 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 0 | 1 |
| Race — Asian | 4 | 2 | 6 |
| Race — Black | 43 | 18 | 61 |
| Race — Native Hawaiian or Pacific Islander | 1 | 0 | 1 |
| Race — White | 104 | 55 | 159 |
| Race — Other | 8 | 3 | 11 |
| Race — Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| United States | 121 | 59 | 180 |
| Spain | 26 | 13 | 39 |
| Portugal | 13 | 6 | 19 |
| United Kingdom | 2 | 2 | 4 |
| Brazil | 1 | 0 | 1 |
| Clinical Status (8-point Ordinal Scale)(Participants) | Remdesivir (RDV) | Placebo | Total |
|---|---|---|---|
| Score: 1 | 0 | 0 | 0 |
| Score: 2 | 0 | 0 | 0 |
| Score: 3 | 0 | 0 | 0 |
| Score: 4 | 36 | 18 | 54 |
| Score: 5 | 97 | 47 | 144 |
| Score: 6 | 30 | 15 | 45 |
| Score: 7 | 0 | 0 | 0 |
| Score: 8 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Mar 2021 to primary completion in Apr 2022, 12 months.
Results were first posted in May 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remdesivir